Inspire® Upper Airway Stimulation (UAS): A Comprehensive Guide for Sleep Professionals and Patients

Inspire® Upper Airway Stimulation (UAS): A Comprehensive Guide for Sleep Professionals and Patients

Author: [MySleepScoring.com]

Target Audience: Sleep Technologists (RPSGT, CPSGT), Sleep Physicians, ENT Specialists, Primary Care Providers, and Patients considering or using Inspire® therapy.

Introduction: Why Inspire Matters to Everyone in Sleep Medicine

As Inspire® Upper Airway Stimulation (UAS) therapy becomes an increasingly common and effective treatment for Obstructive Sleep Apnea (OSA), a clear understanding of its mechanisms, management, and patient experience is vital. For sleep technologists, Inspire represents a paradigm shift from traditional PAP therapy, demanding a new skill set focused on neurostimulation, precise monitoring, and nuanced documentation. For patients, understanding this innovative therapy is key to making informed decisions and achieving successful outcomes.

This article serves as a comprehensive, multi-faceted guide. It provides RPSGT-focused education on sleep lab workflows, titration studies, and scoring, while also offering essential clinical context for providers and clear, empowering information for patients.

What Is Inspire Therapy?

Inspire® is an implantable therapy for select patients with moderate to severe obstructive sleep apnea (OSA) who cannot tolerate or fail positive airway pressure (PAP) therapy.

It is a form of hypoglossal nerve stimulation (HNS) that:

• Senses the patient’s breathing pattern via a sensing lead (or internally in newer models).
• Delivers mild stimulation, precisely timed to inspiration.
• Activates key upper airway dilator muscles, primarily the genioglossus muscle of the tongue.
• Reduces upper airway collapse and obstruction during sleep.

Important Distinction for Technologists & Patients:

✅ Treats obstructive events

❌ Does not treat central sleep apnea

❌ Does not splint the airway like CPAP; instead, it actively opens the airway from within.

Patient Selection: Who is a Candidate?

Not every patient with OSA is a candidate for Inspire. Understanding the selection criteria is crucial for both clinical teams and prospective patients.

Key Selection Elements (as per FDA labeling and clinical guidelines):

• Moderate to severe obstructive sleep apnea (AHI between 15 and 65 events/hour).
• Documented PAP intolerance or failure.
• Minimal central or mixed apnea burden (typically $<25\%$ of total AHI).
• No complete concentric collapse (CCC) at the soft palate on Drug-Induced Sleep Endoscopy (DISE).
• Acceptable BMI (Body Mass Index) and airway anatomy per current FDA labeling (BMI $\le 40$ in many regions/insurance plans, though this can vary).
• Age $\ge 18$ (with some pediatric exceptions for conditions like Down Syndrome).

💡 Why this matters for Technologists: Residual events during Inspire studies often reflect the patient's underlying phenotype or an unoptimized stimulation setting, rather than poor study quality or scoring.

💡 Why this matters for Patients: Thorough screening ensures the best chance of therapy success and minimizes unnecessary procedures.

Anatomy of Inspire: How it Works

The Inspire system typically consists of two implanted components (though newer models integrate sensing):

1. Stimulation Lead: Placed around the hypoglossal nerve (Cranial Nerve XII), it delivers mild electrical pulses to activate the tongue muscles.
2. Sensing Lead (External or Integrated): Placed between the intercostal muscles of the chest (or integrated into the main device in newer Inspire V models), it detects breathing patterns to synchronize stimulation with inspiration.
3. Implantable Pulse Generator (IPG): A small battery-powered device implanted in the chest, it houses the electronics and battery, receiving signals and delivering stimulation.

Visualizing the System:

Here is a simplified diagram of the Inspire system components and their placement.

Types of Sleep Studies Involving Inspire

Sleep technologists may encounter Inspire patients during several types of studies:

1. Pre-Implant Diagnostic PSG:
   • Standard diagnostic study.
   • Scored per AASM rules.
   • Used to establish baseline severity, event phenotype, and ensure candidacy.
2. Post-Implant Activation (Clinic-Based):
   • Typically performed in the sleep clinic, not the lab.
   • Device is activated and initially programmed weeks after surgery to allow for healing.
3. Inspire Titration PSG (Critical Technologist Role):
   • The primary opportunity for lab-based evaluation and optimization.
   • Focuses on assessing therapy effectiveness and fine-tuning parameters.

Inspire Titration PSG: The Technologist’s Role

This study is where the RPSGT's expertise is paramount.

Purpose of the Study:

• Evaluate the reduction of obstructive events (apneas, hypopneas, RERAs).
• Assess sleep continuity and oxygenation.
• Identify and classify residual respiratory events.
• Document patient tolerance, comfort, and any adverse sensations.
• Provide data directly impacting post-study programming decisions.

What Happens During the Study:

• Patient turns Inspire therapy ON using their remote before lights out.
• Crucially: Stimulation parameters (e.g., amplitude, pulse width) are not typically controlled by the technologist during the study. Adjustments are made post-study by the physician based on the technologist's data.
• Newer Systems (Inspire V): The latest Inspire V model integrates the sensing function directly into the IPG, eliminating the need for a separate intercostal sensing lead. Technologists should be aware of this design change.

Key Responsibilities for the Technologist:

• Monitor: Airflow, respiratory effort, SpO₂, and arousals with precision.
• Observe Changes in:
  • Obstructive apneas, hypopneas, and Respiratory Effort Related Arousals (RERAs).
  • Snoring and inspiratory flow limitation patterns.
  • Oxygen desaturation trends and nadir.
• Document:
  • Time therapy initiated and any pauses.
  • Sleep stage–specific therapy response (e.g., efficacy in REM vs. NREM).
  • Positional differences in therapy efficacy (supine vs. non-supine).
  • Arousals related to obstruction versus potential stimulation discomfort.
  • Patient complaints, awakenings, or perceived sensations.
  • Any visible tongue movement.

📌 Important Difference from PAP: You are not titrating pressure — you are meticulously observing and documenting the physiologic response to breath-synchronized neurostimulation.

Scoring Considerations for RPSGTs

AASM Scoring Rules Still Apply:

• Apneas and hypopneas are scored per standard AASM criteria.
• Inspire therapy does not alter AASM scoring definitions.

Nuances Commonly Seen:

• Residual hypopneas may persist despite otherwise effective therapy, often reflecting subtle airway resistance rather than complete collapse.
• Persistent REM-related obstruction: REM sleep's heightened muscle atonia can challenge therapy, leading to more events during this stage.
• Positional variability: Efficacy may differ significantly between supine and non-supine positions.
• Flow limitation patterns: Airflow may change from a "flattened" morphology to a more rounded, but still dynamic, pattern rather than disappearing completely.
• Central Events: Central apneas may become more visible or even slightly increase once obstructive burden is removed. Accurate classification is essential.

Visualizing Airflow Patterns:

The airflow signal with Inspire therapy can look different from both untreated OSA and optimal CPAP.

• Untreated OSA: Characterized by significant inspiratory flow limitation (flattened inspiratory curve), snoring, desaturations, and often RERAs with associated arousals.
• Inspire Therapy (Breath-Synchronized Stimulation): The green bars indicate stimulation synchronized with inspiration, actively opening the airway. The blue line shows improved, more rounded airflow. Hypoglossal nerve activity (red line) shows the response to stimulation.
• What a Tech Sees (Scored Events): Despite therapy, some residual events like hypopneas or RERAs can still occur. The tech's role is to accurately identify and score these according to AASM guidelines, noting oxygen desaturations and associated EEG arousals.

Sleep Architecture and Inspire Therapy

Common observations include:

• Improved sleep continuity and reduced fragmentation once obstruction is managed.
• Reduced respiratory-related arousals (RERAs).
• Variable REM response that is highly patient-specific.
• Occasional stimulation-related microarousals, especially early in therapy or if amplitude is unoptimized. These should be objectively documented.

Patient Comfort & Safety: What to Document

Common Observations:

• Visible tongue movement or mild stimulation sensation (expected).
• Brief awakenings related to initial stimulation (often resolve with adaptation).
• Minor adjustment effects during the night as patients habituate.

Important to Report:

• Persistent awakenings linked to stimulation that disrupt sleep.
• Significant discomfort (e.g., pain, burning, excessive tongue movement).
• Inability to tolerate therapy overnight (document reason and duration).
• Any speech or swallowing complaints during the study if the patient is awake.

Technologist documentation plays a direct role in post-study programming decisions, informing the physician on amplitude adjustments, ramp times, and other therapy settings.

Troubleshooting Guide for Sleep Technologists

Here’s a quick reference for common issues during an Inspire Titration PSG:

Patient Education Script (For Technologists at Hook-Up)

"Hi [Patient Name], welcome to the sleep lab tonight! My name is [Tech Name], and I'll be your technologist. Tonight, we’ll be doing an Inspire titration study.

• Understanding Tonight: This study helps your doctor see how well your Inspire device is working while you sleep, and if any adjustments are needed. It's really important that your device stays on all night, unless you have a problem.
• Your Remote: Please use your remote to turn your Inspire device ON when you're ready for bed. I’ll make a note of the time.
• What to Expect: You might feel a gentle sensation or see your tongue move slightly when the device is active. This is normal. Your therapy is designed to stimulate your tongue muscles and open your airway with each breath.
• My Role: I'll be monitoring your sleep, breathing, and the device's effects from the control room. I won't be changing your device settings tonight – that's your doctor's job after they review the study. My job is to document everything accurately so they have the best information.
• If You Need Me: If you have any significant discomfort, can't sleep, or need help with anything, just let me know through the intercom. We want you to be as comfortable as possible.
• The Morning: We’ll talk about how you felt and your experience with the device in the morning.

Do you have any questions for me before we get started?"

How Inspire Outcomes Are Evaluated

Both objective and subjective measures are crucial for assessing therapy success.

Objective Measures:

• Reduction in AHI (Apnea-Hypopnea Index) to below a clinical threshold (e.g., <15 or <10 events/hour).
• Improvement in ODI (Oxygen Desaturation Index) and SpO₂ nadir.
• Reduced time spent in obstructive events and associated desaturations.

Subjective Measures:

• Patient-reported sleep quality and daytime alertness (e.g., Epworth Sleepiness Scale - ESS).
• Improved tolerance compared to prior PAP therapy.
• Reduction in snoring and witnessed apneas by a bed partner.

Accurate scoring and documentation by the technologist are foundational to these assessments.

Clinical Evidence: The ADHERE Registry

The ADHERE registry is the largest and longest-running post-market surveillance study for hypoglossal nerve stimulation. It provides real-world evidence of Inspire therapy's effectiveness and safety.

Key Findings from ADHERE (Illustrative Data):

• Significant AHI Reduction: Patients in the ADHERE registry consistently show an average AHI reduction of approximately 70-80% from baseline, often decreasing into the mild or normal range.
• Improved ODI: A similar reduction in ODI is observed, indicating improved oxygenation during sleep.
• High Adherence: Therapy adherence is remarkably high, with 80-90% of patients using their device for 4+ hours per night, 6-7 nights per week, a stark contrast to typical PAP adherence rates.
• Sustained Benefit: Benefits are shown to be sustained over multiple years of follow-up.
• Improved QOL: Significant improvements in quality of life metrics, including reduced daytime sleepiness and improved functional outcomes.

This robust real-world data reinforces Inspire's role as an effective, long-term solution for appropriate OSA patients.

Limitations Technologists and Patients Should Understand

• Inspire does not eliminate all respiratory events: Some patients are "partial responders," meaning significant improvement but not complete normalization of AHI.
• Variable Efficacy: Weight changes, sleep position, sleep stage (especially REM), and even alcohol consumption can influence therapy efficacy.
• Ongoing Optimization: Inspire therapy is often a process of ongoing optimization, requiring follow-up and potential programming adjustments. This is expected and normal therapy management, not treatment failure.

Key Takeaways for RPSGTs and Patients

• Inspire is not CPAP — expectations, monitoring, and problem-solving differ significantly.
• Accurate AASM scoring remains essential for all studies.
• Document physiologic response, not assumptions. Your objective observations are invaluable.
• Understand patient phenotype and candidacy to contextualize study findings.
• Your observations directly influence therapy success through informing programming decisions.
• For Patients: Active engagement, consistent device use, and open communication with your clinical team are key to long-term success.

Professional Disclaimer

This content is intended for professional education of sleep technologists and provides general information for patients. It does not replace physician judgment, device-specific protocols, or institutional policies. Inspire® therapy candidacy, programming, and clinical decisions are determined by qualified healthcare providers in accordance with FDA labeling and clinical guidelines.

Additional Images

Here is an image illustrating the patient remote and its basic functions.